A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components

Completed

• Conditions: Dengue Virus; Chikungunya Virus

• Registration Number: NCT02305732
• Lead Sponsor: Cerus Corporation

Brief Summary

The rationale for a Treatment Use Investigational Device Exemption (IDE) of INTERCEPT PCs is to address current gaps in platelet transfusion safety in selected geographic regions. The objective is to provide access to INTERCEPT PCs for patients who might be at risk of transfusion-transmitted infection (TTI) due to Chikungunya virus (CHIKV) and Dengue virus (DENV) in regions in which a substantial proportion of the population has been infected or is at risk of infection by these pathogens (Petersen 2014); and the risk of asymptomatic infection among qualified blood donors is recognized (Stramer 2012, Adda 2014).

The study is designed as a prospective, open label, multi-center, observational study to evaluate the safety and efficacy of INTERCEPT platelet components.

Detailed Description

Upon written informed consent, patients will be transfused with study PCs according to local practices. Each patient will be supported with platelets as clinically indicated in a manner that is consistent with the local standard of care. The study will be conducted in two phases. During the pilot phase, patients will sign informed consent to have study data collected following transfusion with conventional PCs. The objective of the pilot phase is to evaluate study logistics and data collection methods. During the INTERCEPT Treatment Use phase, patients will sign informed consent to receive INTERCEPT PCs, provide blood samples, and collect study data (demographics, transfusion data, and safety data).

Study Timeline

• Study First Submitted: 2014-11-25
• Study First Submitted QC: 2014-11-28
• Study First Posted: 2014-12-03
• Study Start: 2015-03
• Primary Completion: 2016-05
• Study Completion: 2016-05
• Results First Submitted: 2017-05-09
• Status Verified: 2017-12
• Results First Submitted QC: 2018-01-24
• Last Update Submitted: 2018-01-24
• Results First Posted: 2018-10-30
• Last Update Posted: 2018-10-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

• Patients with a serious disease expected to require or requiring a transfusion of platelet component(s)
• Patient population as defined by each Investigator and their institutional review board (IRB).
• Patient provides written informed consent

Exclusion Criteria

• Documented allergy to psoralens
• Neonatal patients treated with phototherapy devices that emit wavelengths less than 425 nm due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen.
• Pregnant women in their third trimester of pregnancy (due to possibility the neonate may need bilirubin light treatment after birth).

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The Proportion of Patients With Any Unrelated Adverse Event	1 year	Unrelated adverse events are defined as adverse events unrelated to the INTERCEPT platelet component transfused.
The Proportion of Transfused INTERCEPT Platelet Components With a Post-treatment Platelet Dose ≥ 3.0×10^11 Platelets.	1 year	INTERCEPT platelet components (PCs) manufactured for this study are leukocyte reduced apheresis PCs processed using the INTERCEPT Blood System (IBS) for platelets. The IBS for platelets is a Class III medical device approved by the FDA for the ex-vivo preparation and storage of pathogen reduced apheresis PCs. The system is used to inactivate a broad range of pathogens, including viruses, bacteria, and protozoan parasites as well as contaminating donor leukocytes. Post-manufacturing, INTERCEPT PCs are either transfused or stored according to blood center standard operating procedures, US FDA, and AABB Guidelines.; Subjects enrolled in this study are transfused with INTERCEPT PCs as dictated by the treating physician. One platelet component was treated as one platelet transfusion for the purpose of data analysis in this study.
The Proportion of Patients With a Confirmed Case of Transfusion-transmitted Chikungunya Virus or Dengue Infection	1 year
The Proportion of Transfused INTERCEPT Platelet Components Associated With Any Transfusion Reactions and/or Unrelated Adverse Event	1 year	Transfusion reactions are defined as adverse events assessed as possibly, likely/probably or certainly related to the INTERCEPT platelet component transfused.; Unrelated adverse events are defined as adverse events unrelated to the INTERCEPT platelet component transfused.; ""1 Transfusion = 1 Intercept Platelet Component".
The Proportion of Patients With Any Transfusion Reactions	1 year	Transfusion reactions are defined as adverse events assessed as possibly, likely/probably or certainly related to the INTERCEPT platelet component transfused.

Trial Locations

Locations (8)

Hospital San Lucas Ponce; 🇵🇷 Ponce, Puerto Rico

Hospital La Concepcion San German; 🇵🇷 San German, Puerto Rico

Centro Cardiovascular de Puerto Rico and the Caribbean; 🇵🇷 San Juan, Puerto Rico

Veteran Administration; 🇵🇷 San Juan, Puerto Rico

Hospital General Menonita de Aibonito; 🇵🇷 Aibonito, Puerto Rico

Center Hospital Manati; 🇵🇷 Manati, Puerto Rico

Hospital General Menonita de Caguas; 🇵🇷 Caguas, Puerto Rico

Hospital General Menonita de Cayey; 🇵🇷 Cayey, Puerto Rico